Transmucosal Nasal Drug Delivery: Systemic Bioavailability of ...

More documents

Recommendations

Info

12 Curriculum vitae During my academic education I attended lectures and practical courses given by following professors and lecturers: Barras JP, Berger Büter K, Betz G, Bienz KA, Bölsterli U, Brunner E, Bruppacher R, Drewe J, Durrer H, Erb P, Ernst B, Fahr A, Folkers G, Günter TW, Gutmann H, Haag-Wackernagel D, Hädener A, Hauser PC, Hersberger K, Huber PR, Hunziker W, Iberg N, Imanidis G, Itin P, Kaden TA, Kessler M, Krähenbühl S, Kress A, Lampert ML, Landmann L, Leu Marseiler R, Leuenberger H, Meier B, Meyer CA, Meyer J, Moroni C, Mühlebach S, Müller HJ, Oelhafen PC, Plattner GR, Rätz-Bravo A, Regeniter A, Renggli V, Saxer A, Schaffner W, Scholer A, Schlienger R, Séquin U, Sigel H, Spornitz UM, Strazewski P, Surber C, Vedani A, Zaugg C, Zuberbühler AD Katja Suter-Zimmermann Page 188 of 188 University of Basel, 2008
Page 1:
TRANSMUCOSAL NASAL DRUG DELIVERY Sy
Page 5 and 6:
Acknowledgments At the Hospital Pha
Page 7:
Index EXPERIMENTAL SECTION 5 Projec
Page 11 and 12:
Summary Summary Transmucosal nasal
Page 13:
Summary Project III: In this random
Page 17:
THEORETICAL SECTION
Page 20 and 21:
1. Nasal drug delivery 1.2 Transmuc
Page 22 and 23:
1. Nasal drug delivery 1.3 Challeng
Page 25 and 26:
2. Impact of anatomy and physiology
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
3. Midazolam 3 Midazolam 3.1 Physic
Page 33 and 34:
3. Midazolam 3.2.1 Indications and
Page 35 and 36:
3. Midazolam Administration of high
Page 37 and 38:
3. Midazolam gastrointestinal tract
Page 39 and 40:
4. Compounding of nasal midazolam p
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49:
Page 53 and 54:
5. Project I: Development of prepar
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67:
Page 70 and 71:
6. Project II: Pharmacokinetic of t
Page 72 and 73:
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 91 and 92:
7. Project III: Transmucosal nasal
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103:
Page 106 and 107:
8 Overall discussion pharmacokineti
Page 108 and 109:
8 Overall discussion considered as
Page 111:
Appendix
Page 114 and 115:
10 Appendix 10.2 Project I 10.2.1 R
Page 116 and 117:
10 Appendix 10.2.4 Specification: M
Page 118 and 119:
10 Appendix 10.2.6 Specification: C
Page 120 and 121:
10 Appendix Katja Suter-Zimmermann
Page 122 and 123:
10 Appendix 10.2.9 Specification: C
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147: 10 Appendix Katja Suter-Zimmermann
Page 150 and 151: 10 Appendix 10.3.2 Case report form
Page 158 and 159: 10 Appendix Frequency 10.3.5 Intens
Page 160 and 161: 10 Appendix 10.3.7 Serumconcentrati
Page 162 and 163: 10 Appendix Identification midazola
Page 168 and 169: 10 Appendix 10.3.8 Midazolam serum
Page 170 and 171: 10 Appendix 10.3.10 Nasal delivery
Page 174 and 175: 10 Appendix 10.4.3 Flowchart: multi
Page 185 and 186: 11 References 11 References Abrams,
Page 187 and 188: 11 References Erjefalt, J.S., I. Er
Page 189 and 190: 11 References Irie, T. and K. Uekam
Page 191 and 192: 11 References Malinovsky, J.M., C.
Page 193 and 194: 11 References Scheepers, M., B. Sch
Page 195: 12 Curriculum vitae 12 Curriculum v
show all

Transmucosal Nasal Drug Delivery: Systemic Bioavailability of ...

Create successful ePaper yourself

Delete template?

Save as template?